A milestone for medicines regulation, pharmaceutical manufacturing competitiveness, and Africa’s health product ecosystem

A Historic Milestone for Zimbabwe and Africa

MCAZ achieved WHO GBT ML4 status following a WHO assessment mission in April–May 2026, making Zimbabwe the first African country and only the fourth globally—after Singapore, South Korea, and Saudi Arabia—to attain the highest level of regulatory maturity.

This achievement places Zimbabwe among a select group of countries globally with advanced and continuously improving regulatory systems and marks a significant moment not only for Zimbabwe, but also for Africa’s broader pharmaceutical and health systems agenda. For Africa, the achievement is especially significant because it demonstrates that globally competitive regulatory capabilities can be built and sustained in emerging-market contexts.

Understanding WHO GBT and Maturity Levels

The Global Benchmarking Tool (GBT) is developed and used by the WHO to evaluate National Regulatory Authorities’ (NRAs) capacity across core functions such as marketing authorization, pharmacovigilance, market control, licensing of establishments, regulatory inspections, laboratory testing, and clinical-trials oversight.

WHO classifies regulatory systems across maturity levels –

• ML1 reflects the existence of some regulatory elements
• ML2 indicates an evolving system
• ML3 represents a stable, well-functioning and integrated system, and
• ML4 represents an advanced regulatory system with strong performance and a commitment to continuous improvement.

As of WHO’s April 2026 technical listing, countries operating at ML3 and ML4 represented only a subset of national regulatory authorities worldwide. Nine African NRAs have achieved WHO GBT ML3, reflecting growing regulatory maturity across the continent. Focused investments in regulatory system strengthening are delivering tangible results across Africa

Zimbabwe’s Regulatory Journey: From ML3 to ML4

Zimbabwe’s ML4 achievement builds on sustained regulatory-strengthening journey. MCAZ had previously reached WHO ML3 for regulation of medicines and vaccines, becoming the sixth African NRA to demonstrate a stable and integrated regulatory system capable of effectively performing essential oversight functions.

Progressing to ML4 reflected sustained government commitment, investments in regulatory workforce and systems, improved institutional governance, strengthened inspection capacity, and increased emphasis on quality-management systems.

Setting a Benchmark for Africa and Emerging Markets

Zimbabwe’s achievement sends a powerful signal to African and emerging-market regulators: regulatory excellence is achievable when institutions are supported by sustained political commitment, clear mandates, capable technical staff, strong quality systems, and international collaboration.

For Africa, stronger regulators can contribute to regional harmonization, implementation of the African Medicines Agency agenda, improved reliance mechanisms, faster access to quality-assured products, and stronger local manufacturing ecosystems. Zimbabwe’s progress can therefore serve as both a national asset and a continental reference point.

Why This Matters for Public Health

At its core, regulatory maturity matters because it protects patients. A strong regulatory authority helps ensure that medicines and medical products entering the market are safe, effective, and consistently manufactured to quality standards. It strengthens market surveillance, pharmacovigilance, product authorization, clinical-trial oversight, and inspection systems.

The benefits extend beyond regulation itself – such as improved access to quality-assured medicines, greater public trust in health systems, stronger safeguards against substandard and falsified products, and more robust preparedness for health emergencies.

Implications for Pharmaceutical Manufacturing in Zimbabwe

Zimbabwe’s success reflects a broader commitment to strengthening health systems and regulatory institutions across Africa. Strong regulatory systems are increasingly recognized as foundational enablers of universal health coverage, local manufacturing value chain development, pandemic preparedness and supply security.

Increased Investor Confidence – Attracts pharmaceutical and biotech investments.

ML4 status is a major enabler for pharmaceutical manufacturing. Investors and manufacturers consider regulatory capacity when deciding where to locate production, clinical research, quality-control activities, and regional operations. A credible and internationally recognized regulator can reduce uncertainty, strengthen confidence in product oversight, and improve the overall investment case.

Enhanced Regulatory Reliance and Recognition

ML4 status strengthens opportunities for regulatory reliance and recognition frameworks where regulatory decisions can be trusted and leveraged by other authorities which can lead to reduced duplication of assessments, and greater regional cooperation.

Improved competitiveness in regional and international markets

Zimbabwe’s ML4 status strengthens its position as a gateway for quality-assured pharmaceutical products. It is also a key milestone toward designation as a WHO Listed Authority (WLA), replacing the erstwhile Stringent Regulatory Authority (SRA) classification. As WLA gains recognition as a credible pathway for global procurement and donor-funded programs, it further enhances Zimbabwe’s attractiveness as a manufacturing and export hub.

Realizing this opportunity will require complementary ecosystem enablers, including manufacturing infrastructure, skilled talent, financing, quality-control laboratories, clinical research capacity, and policies that support local production. Nevertheless, ML4 provides a strong institutional foundation to accelerate pharmaceutical development.

Way Forward: Turning Recognition into Ecosystem Development

While achieving ML4 is a remarkable accomplishment, sustaining it will require continuous efforts. WHO officials have emphasized that maintaining ML4 status demands ongoing commitment to quality, innovation, and continuous improvement. Zimbabwe’s next step should be to convert regulatory success into broader ecosystem development for health products.

Key priorities include –

Continued investments in workforce development (inspectors, laboratory professionals, pharmacovigilance specialists, and regulatory scientists) alongside investments laboratory testing, digital systems, and quality management

Support for local manufacturing and technology transfer – Zimbabwe can leverage its regulatory strengths to nurture domestic pharmaceutical production and attract strategic manufacturing investments; and

Regional collaboration – Partnerships with neighboring regulators, the African Medicines Agency, and regional economic communities can amplify the impact of Zimbabwe’s regulatory leadership.

Conclusion

Zimbabwe’s attainment of WHO Maturity Level 4 is a defining moment for MCAZ, for Zimbabwe’s health system, and for Africa’s regulatory landscape. It validates years of institutional strengthening and positions the country as a credible regulatory leader in medicines and medical products.

The strategic value of this milestone lies in what comes next: sustaining regulatory excellence, building manufacturing capabilities, improving access to quality-assured products, supporting regional reliance, and positioning Zimbabwe as a trusted partner in Africa’s pharmaceutical transformation. If Zimbabwe can align regulatory excellence with industrial policy, health financing, procurement, and private-sector investment, ML4 can become more than a recognition milestone. It can become a platform for improved access, stronger public health outcomes, and a more competitive pharmaceutical manufacturing ecosystem.